<unk>  (PF-04950615; RN316) is a humanized monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 and is an investigational agent for the reduction of LDL-C levels in patients with hypercholesterolemia.
Bococizumab
Tocilizumab
Caplacizumab
Ixekizumab
Atezolizumab
Tildrakizumab
Risankizumab
Mogamulizumab